Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Urodynamix: Cross of 1,480,000 common shares effected through Canaccord Capital

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.

30 Sep 2009

Sexual satisfaction and general well-being linked: Study

Pre- and post-menopausal women who self-rated themselves as being sexually satisfied had a higher overall psychological well-being score and scores for "positive well-being" and "vitality," compared with sexually dissatisfied women in a study of 295 women sexually active more than twice a month. The study, published today in The Journal of Sexual Medicine, also uncovered a positive association between age and well-being, but a negative association for general health.

30 Sep 2009

Urodynamix closes $1.5 million non-brokered private placement for common shares

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it has closed a $1.5 million non-brokered private placement for 30,000,000 common shares previously reported on September 11, 2009.

29 Sep 2009

$Diabetic patients face increased risk of bone fractures$

Diabetic patients face increased risk of bone fractures

Current research suggests that the inflammatory molecule TNF-α may contribute to delayed bone fracture healing in diabetics. The related report by Alblowi et al, "High Levels of TNF-α Contribute to Accelerated Loss of Cartilage in Diabetic Fracture Healing" appears in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Androgen deficiency linked to diabetes and cardiovascular diseases

Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD). These findings appear in the September/October issue of the Journal of Andrology.

25 Sep 2009

Results of American Medical Systems Holdings' exchange offer announced

American Medical Systems Holdings, Inc. (NASDAQ: AMMD) (the “Company”), today announced the results of its exchange offer (the “Exchange Offer”) in which the Company offered $1,000 principal amount of its newly issued 4.00% Convertible Senior Subordinated Notes due 2041 (the “2041 Notes”) in exchange for each $1,000 principal amount of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 (the “2036 Notes”), for up to $250 million, and no less than $100 million, aggregate principal amount of 2036 Notes.

18 Sep 2009

Study reveals that older widowers are likely to be diagnosed with a STD

Widowers take care: Older men who have recently lost their wives are more likely than still-married peers to be diagnosed with a sexually transmitted disease (STD), according to a new study.

18 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.

8 Sep 2009

FDA extends review period for Endo Pharmaceuticals' testosterone undecanoate

Endo Pharmaceuticals announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the agency has extended its review period for its long-acting testosterone undecanoate injection for men diagnosed with hypogonadism, from Sept. 2, 2009 to Dec. 2, 2009.

3 Sep 2009

Rizer XL's male enhancement formula increases sexual desire, pleasure and performance

Increasing pressure on men to perform sexually and higher expectations of men's sexual performance from women has led to an astounding rise in sales, says Rizer XL, the leading provider of premium male enhancement pills.

27 Aug 2009

Studies reveal that obese men are at increased risk for erectile dysfunction

Obese men are at increased risk for erectile dysfunction (ED), likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity, as described in a timely article published in Obesity and Weight Management, a journalzine published by Mary Ann Liebert, Inc.

25 Aug 2009

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

24 Aug 2009

Saskatchewan government makes insulin detemir more accessible to residents

The Canadian Diabetes Association applauds the Government of Saskatchewan for increasing access to insulin detemir for residents of Saskatchewan living with diabetes. Insulin detemir, also known as Levemir, has been added to the Saskatchewan Drug Formulary, under Exception Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised Exception Drug Status Criteria.

20 Aug 2009

VIVUS reports Q2 2009 financials

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter ended June 30, 2009.

11 Aug 2009

Scientists investigate health benefits of molecule associated with male sexual arousal

Medical scientists at the University of Leicester are investigating how signalling molecules known to control blood pressure and penile erection act to regulate brain function and which have potential for treatments of migraine, chronic pain, epilepsy and Alzheimer's disease.

24 Jun 2009

New perspective on the causes, effects and potential treatment of sexual dysfunction

Couples' treatment for sexual problems and other innovative approaches to improving sexual health for men and women are on the agenda of sexual medicine experts.

23 Jun 2009

Light therapy as a treatment for sexual dysfunctions

Although we are still far from knowing exactly where and how the pineal suppressive role is exerted, the fact that the gland exerts an inhibitory function on the reproductive axis is widely accepted. In fact, the pineal seems to exert its hormonal effect at different levels of the reproductive axis, both at the hypothalamic-pituitary level and at the gonadal level, where melatonin receptors have also been found.

9 Jun 2009

Tadalafil may improve lower urinary tract symptoms in men with benign prostatic hyperplasia

Relative symptom improvement in the IPSS also was significantly better in the tadalafil group. At the end of the study, the proportion of obstructed patients in the placebo group increased, while the proportion in the tadalafil group decreased.

26 Apr 2009

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).

26 Apr 2009

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Urodynamix: Cross of 1,480,000 common shares effected through Canaccord Capital

Sexual satisfaction and general well-being linked: Study

Urodynamix closes $1.5 million non-brokered private placement for common shares

Diabetic patients face increased risk of bone fractures

Androgen deficiency linked to diabetes and cardiovascular diseases

Results of American Medical Systems Holdings' exchange offer announced

Study reveals that older widowers are likely to be diagnosed with a STD

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

FDA extends review period for Endo Pharmaceuticals' testosterone undecanoate

Rizer XL's male enhancement formula increases sexual desire, pleasure and performance

Studies reveal that obese men are at increased risk for erectile dysfunction

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

Saskatchewan government makes insulin detemir more accessible to residents

VIVUS reports Q2 2009 financials

Scientists investigate health benefits of molecule associated with male sexual arousal

New perspective on the causes, effects and potential treatment of sexual dysfunction

Light therapy as a treatment for sexual dysfunctions

Tadalafil may improve lower urinary tract symptoms in men with benign prostatic hyperplasia

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in